person
as of 2026-07-01Inder Kaul, MD
at a glance
Roles: Study Director, Author
KOL signal score 30
15 publications · 7 high-value
Cross-drug reach: 1 competitor drugs
Synthesized from structured facts only — each point cited above.
Profile
Affiliation
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Roles
Study Director, Author
KOL signal
30
Publications
15 (7 high-value)
Trial investigator
no
Publishes on
1 drugs
Trials led
3
An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)
NCT04820309Phase 3Completed
Publications & congress
15
Long-Term Safety and Efficacy of Xanomeline and Trospium Chloride in Schizophrenia: A 52-Week Open-Label Extension Trial.
The American journal of psychiatry · 2026 · high-value
Long-term efficacy, safety, and tolerability of xanomeline and trospium chloride in schizophrenia: A 52-week, open-label trial (EMERGENT-5).
Schizophrenia research · 2026 · high-value
Xanomeline and Trospium Chloride for the Treatment of Agitation Associated With Schizophrenia: PANSS-Excited Component Results From 3 Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials.
The Journal of clinical psychiatry · 2025 · high-value
Safety and Tolerability of Xanomeline and Trospium Chloride in Schizophrenia: Pooled Results From the 5-Week, Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials.
The Journal of clinical psychiatry · 2025 · high-value
Efficacy of KarXT on negative symptoms in acute schizophrenia: A post hoc analysis of pooled data from 3 trials.
Schizophrenia research · 2024 · high-value
Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia: A Randomized Clinical Trial.
JAMA psychiatry · 2024 · high-value
Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial.
Lancet (London, England) · 2024 · high-value
A Qualitative Investigation of the Experience of Taking Xanomeline and Trospium Chloride for Schizophrenia, Part 2: Perceived Changes in Subjective Quality of Life and Medication Satisfaction.
Schizophrenia bulletin open · 2026
Effects of Xanomeline and Trospium Chloride for Negative Symptoms Associated With Physical Activity in Younger and Older Adults with Schizophrenia: Results From a 52-Week, Open-label Clinical Trial.
Schizophrenia research · 2026
A Qualitative Investigation of the Experience of Taking Xanomeline and Trospium Chloride for Schizophrenia, Part 1: Perceived Impact on Symptoms.
Schizophrenia bulletin open · 2026
Low incidence of extrapyramidal symptoms following treatment with a muscarinic agonist medication for schizophrenia.
Schizophrenia research · 2026
Capturing changes in social functioning and positive affect using ecological momentary assessment during a 12-month trial of xanomeline and trospium chloride in schizophrenia.
Schizophrenia research · 2025
From theory to therapy: unlocking the potential of muscarinic receptor activation in schizophrenia with the dual M1/M4 muscarinic receptor agonist xanomeline and trospium chloride and insights from clinical trials.
The international journal of neuropsychopharmacology · 2025
Author Correction: Efficacy of xanomeline and trospium chloride in schizophrenia: pooled results from three 5-week, randomized, double-blind, placebo-controlled, EMERGENT trials.
Schizophrenia (Heidelberg, Germany) · 2025
Efficacy of xanomeline and trospium chloride in schizophrenia: pooled results from three 5-week, randomized, double-blind, placebo-controlled, EMERGENT trials.
Schizophrenia (Heidelberg, Germany) · 2024
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
publishes on
STUDY_DIRECTOR